Image
Recommendation
Sentinel node biopsy – Inflammatory breast cancer
Sentinel node biopsy should not be performed in patients who have inflammatory breast cancer.
There are insufficient data to change the 2005 recommendation that clinicians should not perform SNB [SLNB] for women who have early-stage breast cancer and are in the following circumstances: Inflammatory breast cancer
There is some confidence that the recommendation offers the best current guidance for practice. This is based on (1) limited evidence for a true net effect (eg, benefits exceed harms); (2) consistent results, but with important exceptions; (3) concerns about study quality; and/or (4) the extent of panelists’ agreement. Other considerations (discussed in the guideline’s literature review and analyses) may also warrant a weak recommendation
How this guidance was developed
This recommendation was adopted from the ASCO 2017 guidelines (US). The source recommendation was based on a systematic review of the evidence conducted to July 2016 and was graded ‘weak’ (using SIGN methods) by the source guideline authors. The source recommendation was accepted with minor stylistic changes, but with no changes to the meaning or tone of the source recommendation.
Sentinel node biopsy – Inflammatory breast cancer
Recommendation
Sentinel node biopsy should not be performed in patients who have inflammatory breast cancer.
Principles in action
Safe and quality care
This recommendation was adopted from the ASCO 2017 guidelines (US). The source recommendation was based on a systematic review of the evidence conducted to July 2016 and was graded ‘weak’ (using SIGN methods) by the source guideline authors. The source recommendation was accepted with minor stylistic changes, but with no changes to the meaning or tone of the source recommendation.